文献速递肺外科

COVID-19幸存者的肺实质病理变化研究

Pulmonary Parenchymal Changes in COVID-19 Survivors.
PubMed 文献 · Ann Thorac Surg · 2021-07-31

这项多中心观察性研究纳入11例康复后接受择期肺切除术的COVID-19幸存者,与年龄和术式匹配的5例从未感染COVID-19的对照组及3例终末期COVID-19患者进行比较。盲法肺病理学家检查肺实质四个区域,未发现幸存者与对照组之间存在差异;终末期组则显示纤维化弥漫性肺泡损伤等改变。结论认为未发现提示永久性肺损伤的急性期后组织病理学改变。

要点

  • COVID-19幸存者康复后肺实质组织病理学与未感染者无差异
  • 终末期COVID-19患者可见纤维化弥漫性肺泡损伤等改变
  • 结果对康复后无症状的COVID-19幸存者具有安抚意义

核心结论

  • 在COVID-19幸存者中未发现提示永久性肺损伤的明确急性期后组织病理学改变。

研究设计与样本

  • 多中心观察性研究,纳入11例康复后接受择期肺切除术的成人COVID-19幸存者,与年龄和术式匹配的5例从未感染COVID-19对照组及3例终末期COVID-19患者比较。
  • 由盲法肺病理学家检查肺实质,聚焦气道、肺泡、间质和血管四个区域。

主要发现

  • 择期肺切除术在COVID-19诊断后中位68.5天(范围24-142天)进行,感染严重程度为无症状4例、中度4例、重度3例。
  • 最常见手术为肺叶切除术(75%)。
  • COVID-19幸存者与对照组在所有检查区域的肺实质组织病理学上无差异。
  • 终末期COVID-19组显示纤维化弥漫性肺泡损伤伴肺泡内巨噬细胞、机化性肺炎和局灶性间质气肿。

临床怎么用

  • 对于康复后无症状的COVID-19幸存者,肺实质组织病理学未见永久性损伤证据,可提供 reassuring 信息。

局限性

  • 样本量小(幸存者11例、对照组5例、终末期组3例),可能限制统计效能和普遍性。
  • 研究对象为接受择期肺切除术的患者,可能存在选择偏倚。
  • 中位随访时间68.5天,不足以评估更长期的组织病理学变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: As the COVID-19 pandemic moves into the survivorship phase, questions regarding long-term lung damage remain unanswered. Previous histopathologic studies are limited to autopsy reports. We studied lung specimens from COVID-19 survivors who underwent elective lung resections to determine whether postacute histopathologic changes are present. METHODS: This multicenter observational study included 11 adult COVID-19 survivors who had recovered but subsequently underwent unrelated elective lung resection for indeterminate lung nodules or lung cancer. We compared these against an age- and procedure-matched control group who never contracted COVID-19 (n = 5) and an end-stage COVID-19 group (n = 3). A blinded pulmonary pathologist examined the lung parenchyma focusing on 4 compartments: airways, alveoli, interstitium, and vasculature. RESULTS: Elective lung resection was performed in 11 COVID-19 survivors with asymptomatic (n = 4), moderate (n = 4), and severe (n = 3) COVID-19 infections at a median 68.5 days (range 24-142 days) after the COVID-19 diagnosis. The most common operation was lobectomy (75%). Histopathologic examination identified no differences between the lung parenchyma of COVID-19 survivors and controls across all compartments examined. Conversely, patients in the end-stage COVID-19 group showed fibrotic diffuse alveolar damage with intra-alveolar macrophages, organizing pneumonia, and focal interstitial emphysema. CONCLUSIONS: In this study to examine the lung parenchyma of COVID-19 survivors, we did not find distinct postacute histopathologic changes to suggest permanent pulmonary damage. These results are reassuring for COVID-19 survivors who recover and become asymptomatic.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Diaz A, Bujnowski D, McMullen P, et al. Pulmonary Parenchymal Changes in COVID-19 Survivors. Ann Thorac Surg. 2021. PMID: 34343471. doi:10.1016/j.athoracsur.2021.06.076

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。